Thomas Mullen

Thomas Mullen has held various roles in the medical and genetics field since 2008. Their career began as a Clinical Molecular Genetics Fellow at Harvard Medical School, followed by a Postdoctoral Fellow in Medical and Population Genetics at the Broad Institute of MIT and Harvard. In 2010, they became an Instructor and Assistant Laboratory Director at Massachusetts General Hospital. From 2012 to 2013, they served as the Director of the Clinical Molecular Genetics Fellowship Program at Harvard Medical School, and then as a Laboratory Director and Technical Director, and Associate Laboratory Director and Technical Director at Good Start Genetics. From 2016 to 2017, they held various roles at the Broad Institute of MIT and Harvard, including Clinical Laboratory Director - Broad Genomics and Senior Analyst - Broad Center for Mendelian Genomics. From 2017 to 2021, they worked at Quest Diagnostics as Executive Scientific Director, Senior Scientific Director, and Senior Director, Genetics. Most recently, in 2021 they became the Vice President, Head of Translational Assay Operations and Clinical Lab at Harbinger Health, and will become the Chief Scientific Officer at SeQure Dx in 2022.

Thomas Mullen obtained a Bachelor of Science (B.S.) in Biology/Biological Sciences, General from Northeastern University in 1999. Thomas then went on to earn a Master of Science (M.S.) in Pathobiology from the University of Connecticut in 2002. After that, they completed a Doctor of Philosophy (Ph.D.) in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill in 2008. In 2011, Mullen obtained a certification in Molecular Diagnostics from the American Board of Medical Genetics and Genomics.